- Home
- UTHR vs BCH Comparison
UTHR vs BCH Comparison
Compare UTHR & BCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- BCH
- Stock Information
- Founded
- UTHR 1996
- BCH 1893
- Country
- UTHR United States
- BCH Chile
- Employees
- UTHR N/A
- BCH N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- BCH Commercial Banks
- Sector
- UTHR Health Care
- BCH Finance
- Exchange
- UTHR Nasdaq
- BCH Nasdaq
- Market Cap
- UTHR 14.4B
- BCH 13.1B
- IPO Year
- UTHR 1999
- BCH 2002
- Fundamental
- Price
- UTHR $284.73
- BCH $27.97
- Analyst Decision
- UTHR Buy
- BCH Hold
- Analyst Count
- UTHR 12
- BCH 1
- Target Price
- UTHR $388.25
- BCH $23.00
- AVG Volume (30 Days)
- UTHR 499.4K
- BCH 392.9K
- Earning Date
- UTHR 04-30-2025
- BCH 04-29-2025
- Dividend Yield
- UTHR N/A
- BCH 7.48%
- EPS Growth
- UTHR 24.38
- BCH N/A
- EPS
- UTHR 24.64
- BCH 0.01
- Revenue
- UTHR $2,877,400,000.00
- BCH $2,816,160,332.00
- Revenue This Year
- UTHR $11.52
- BCH $18.71
- Revenue Next Year
- UTHR $6.08
- BCH $5.56
- P/E Ratio
- UTHR $11.56
- BCH $10.92
- Revenue Growth
- UTHR 23.63
- BCH N/A
- 52 Week Low
- UTHR $233.28
- BCH $21.37
- 52 Week High
- UTHR $417.82
- BCH $28.64
- Technical
- Relative Strength Index (RSI)
- UTHR 37.49
- BCH 60.19
- Support Level
- UTHR $266.98
- BCH $23.66
- Resistance Level
- UTHR $288.54
- BCH $27.40
- Average True Range (ATR)
- UTHR 14.43
- BCH 0.87
- MACD
- UTHR -0.15
- BCH 0.19
- Stochastic Oscillator
- UTHR 38.23
- BCH 94.73
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About BCH Banco De Chile ADS
Operating under three separate brand names (Banco de Chile, Banco Edwards-Citi, and Banco CrediChile) Banco de Chile is the second largest in the country by loans and third largest by deposits. Banco de Chile generates most of its net interest income (roughly 60% of total revenue) from its mortgage, unsecured consumer credit lines, and commercial loans, with 25% of its outstanding loans being made to firms with more than 10,000 million CLP in revenue. Outside of its banking business, Banco de Chile is the largest asset manager in the country and one of the largest security brokerages, supporting its substantial fee-based revenue.